Classification
- Anatomical main groupJAnti-infectives for systemic use
- Therapeutic subgroupJ05
- Pharmacological subgroupJ05A
- Chemical subgroupJ05AP
- Chemical substanceJ05AP08Sofosbuvir
Where it is registered
Each register and historical list with its number of registrations and a few of them.
Netherlands
CBG-MEB · 14 registrations
- Sovaldi 150 mg, granulaatGranulaat · Gilead Sciences Ireland UC
- Sovaldi 200 mg, filmomhulde tabletFilmomhulde tablet · Gilead Sciences Ireland UC
- Sovaldi 200 mg, granulaatGranulaat · Gilead Sciences Ireland UC
- Sovaldi 400 mg filmomhulde tablettenFilmomhulde tablet · Gilead Sciences Ireland UC
Brazil
Anvisa · 9 registrations
At a glance
- ATC code
- J05AP08
- ATC group
- Anti-infectives for systemic use
- Registers
- 10
- Historical lists
- 2
- Registrations
- 65
- With their own page
- 53
- Companies
- 17
All medicines with Sofosbuvir
Human medicines from every register that match Sofosbuvir by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
65 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Sofosbuvir | Brazil | Authorised | Blanver Farmoquimica e Farmaceutica S.A. | ||
| sofosbuvir | Brazil | Authorised | Fundação Para O Remédio Popular - Furp | ||
| sofosbuvir | Brazil | Authorised | Ems S/A | ||
| sofosbuvir | Brazil | Authorised | Fundação Oswaldo Cruz | ||
| Sofosbuvir | United States | 400MG | tablet | Not marketed | Teva Pharms USA INC |
| Sovaldi | United States | 150MG/PACKET, 200MG/PACKET | pellets | Marketed | Gilead Sciences INC |
| Sovaldi | United States | 200MG, 400MG | tablet | Marketed | Gilead Sciences INC |
| EpclusaCombination | United States | 150MG; 37.5MG/PACKET, 200MG; 50MG/PACKET | pellets | Marketed | Gilead Sciences INC |
| EpclusaCombination | United States | 200MG; 50MG, 400MG; 100MG | tablet | Marketed | Gilead Sciences INC |
| VoseviCombination | United States | 400MG; 100MG; 100MG | tablet | Marketed | Gilead Sciences INC |
| Sovaldi | European Union | Authorised | Gilead Sciences Ireland UC | ||
| HarvoniCombination | United States | 45MG; 200MG, 90MG; 400MG | tablet | Marketed | Gilead Sciences INC |
| Epclusa 200 MG/50 MG Granulado Recubierto en SobreCombination | Spain | 200 mg + 50 mg | granulado recubierto | Marketed | Gilead Sciences Ireland Unlimited Company |
| SOVALDI 400mg comprimidos recubiertos con pelicula | Spain | 400 mg | comprimido recubierto con película | Marketed | Gilead Sciences Ireland Unlimited Company |
| Epclusa 150 MG/37,5 MG Granulado Recubierto en SobreCombination | Spain | 150 mg + 37,5 mg | granulado recubierto | Marketed | Gilead Sciences Ireland Unlimited Company |
| Sovaldi | Canada | 400 MG | Tablet | Marketed | Gilead Sciences Canada INC |
| Sovaldi 150 mg, granulaat | Netherlands | Granulaat | Authorised | Gilead Sciences Ireland UC | |
| Sovaldi 200 mg, granulaat | Netherlands | Granulaat | Authorised | Gilead Sciences Ireland UC | |
| EpclusaCombination | European Union | Authorised | Gilead Sciences Ireland UC | ||
| Epclusa 400 MG/100 MG Comprimidos Recubiertos con PeliculaCombination | Spain | 400 mg + 100 mg | comprimido recubierto con película | Marketed | Gilead Sciences Ireland Unlimited Company |
| Epclusa 400 MG/100 MG Comprimidos Recubiertos con PeliculaCombination | Spain | 400 mg + 100 mg | comprimido recubierto con película | Marketed | Gilead Sciences Ireland Unlimited Company |
| Epclusa 400 MG/100 MG Comprimidos Recubiertos con PeliculaCombination | Spain | 400 mg + 100 mg | comprimido recubierto con película | Marketed | Gilead Sciences Ireland Unlimited Company |
| HarvoniCombination | European Union | Authorised | Gilead Sciences Ireland UC | ||
| Harvoni 90 MG/400 MG Comprimidos Recubiertos con PeliculaCombination | Spain | 90 mg + 400 mg | comprimido recubierto con película | Marketed | Gilead Sciences Ireland Unlimited Company |
| VoseviCombination | European Union | Authorised | Gilead Sciences Ireland UC |